Lung Cancer

Solange Peters, MD, PhD, outlines why docetaxel still anchors second-line therapy in NSCLC and where biomarker retesting could move the field.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.

Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.

Xiuning Le, MD, PhD, discusses treatment selection among targeted therapies for HER2-mutant NSCLC.

David Gerber, MD, discusses the evolution of ALK TKIs and the central nervous system toxicity tradeoffs seen with later-generation agents in NSCLC.

Wen Wee Ma, MBBS, discusses the potential advantages of inhaled KB707 and the rationale behind investigating it in non–small cell lung cancer.

The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.

The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.

New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.

Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.

Narjust Florez, MD, discusses a trilingual, multidisciplinary workshop that was held at the 2026 ASCO Annual Meeting.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Joshua K. Sabari, MD, discusses the complexities of managing SCLC across both academic and community settings.

Narjust Florez, MD, discusses how the FDA approval of zidesamtinib in locally advanced or metastatic ROS1-positive NSCLC is an example of the fast pace of clinical oncology.

Jay M. Lee, MD, discusses the role of ctDNA in guiding surveillance and treatment escalation decisions in resected NSCLC.

Amy L. Cummings, MD, discusses patient selection for adjuvant immunotherapy in resectable non–small cell lung cancer.

The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.

China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.

An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.

An OncLive workshop covered practice-changing ROS1- and ALK-directed data in NSCLC shared at ASCO 2026 and beyond.

Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.

Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.

The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.